Switzerland· 68977001

Akeega

A niraparib and abiraterone product containing niraparibum, abirateroni acetas, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01XK52

Checked against BAG Spezialitätenliste (Switzerland) on September 12, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about niraparibum, abirateroni acetasAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Niraparib and abiraterone is registered in 11 of 19 countries.

Countries holding a registration under ATC L01XK52 (niraparib and abiraterone), each read from that country’s own register.

This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
7 of them publish a price we can compare per daily dose

Search niraparib and abiraterone products by name

Niraparib and abiraterone · ATC L01XK52

11 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Norwayprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)

Active substance: niraparibum, abirateroni acetas
Manufacturer: —
Country: Switzerland (CH)
ATC code: L01XK52
ATC class: Niraparib and abiraterone
Swissmedic category: A
Reimbursed: Yes
Source register: BAG Spezialitätenliste (Switzerland)
Last checked: September 12, 2026

Packs & prices · 1

1 priced

gtin
7680689770017
Blist 56 Stk
CHF 4523.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Niraparib and abiraterone in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All niraparib and abiraterone products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Akeega
Liechtenstein · Akeega
Norway · Akeega

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/bdb14394-480a-44fa-b41c-8e4c59fa8c75
GET /v1/drugs/bdb14394-480a-44fa-b41c-8e4c59fa8c75?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "niraparibum 50 mg + abirateroni acetas 500 mg",
  "valid_from": "2026-08-01",
  "limitations": "[{\"description\":\"<p class=\\\"MsoNormal\\\"><a style=\\\"mso-comment-reference: RK_1; mso-comment-date: 20260716T1547;\\\"><strong><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">F&uuml;r alle verg&uuml;tungspflichtigen Indikationen gilt:</span></strong></a></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">Nur nach Verordnung durch einen Facharzt der Urologie oder Onkologie und nach Kostengutsprache durch den Krankenversicherer nach vorg&auml;ngiger Konsultation des Vertrauensarztes.</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">Vor Beginn der Behandlung mit AKEEGA muss der positive BRCA-Status mit einer validierten Testmethode best&auml;tigt worden sein.</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">Bei vorg&auml;ngiger Behandlung mit einem PARP-Inhibitor wird AKEEGA nicht verg&uuml;tet.</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">Die Verg&uuml;tung der Behandlung erfolgt bis zur Krankheitsprogression oder bis zum Auftreten inakzeptabler Toxizit&auml;t.</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">Eine Kostengutsprache hat den entsprechenden Indikationscode (21716.XX) zu enthalten.</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">&nbsp;</span></span></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"mso-comment-continuation: 1;\\\"><span style=\\\"font-size: 10.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: DE-CH; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\\\">Die Zulassungsinhaberin Janssen-Cilag AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin f&uuml;r jede bezogene Packung AKEEGA einen Betrag von&nbsp;<span style=\\\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">Fr. 712.47</span> zur&uuml;ck. Die Mehrwertsteuer kann nicht zus&auml;tzlich zu diesem Anteil des Fabrikabgabepreises zur&uuml;ckgefordert werden. Die Aufforderung zur R&uuml;ckerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.</span></span></p>\",\"costApproval\":null,\"indication\":\"21716.XX\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":\"2027-08-31\"},{\"description\":\"<p class=\\\"MsoNormal\\\"><strong><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">mCRPC BRCA-Genver&auml;nderungen</span></strong></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast;\\\">AKEEGA wird verg&uuml;tet in Kombination mit einer Androgendeprivationstherapie (ADT) und Prednison oder Prednisolon zur Erstlinienbehandlung von asymptomatischen oder mild symptomatischen, erwachsenen Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC) mit BRCA-Genver&auml;nderungen und ohne viszerale Metastasen, bei welchen eine Chemotherapie klinisch nicht indiziert ist.</span></p>\\n<p class=\\\"MsoNormal\\\"><a style=\\\"mso-comment-reference: RK_1; mso-comment-date: 20260716T1547;\\\"><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu &uuml;bermitteln.</span></a></p>\",\"costApproval\":null,\"indication\":\"21716.01\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":\"2027-08-31\"},{\"description\":\"<p class=\\\"MsoNormal\\\"><strong><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">mHSPC BRCA2-Genver&auml;nderungen</span></strong></p>\\n<p class=\\\"MsoNormal\\\"><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">AKEEGA wird verg&uuml;tet in Kombination mit einer Androgendeprivationstherapie (ADT) und Prednison oder Prednisolon zur Behandlung von erwachsenen Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC) mit BRCA2-Genver&auml;nderungen.</span></p>\\n<p class=\\\"MsoNormal\\\"><a style=\\\"mso-comment-reference: RK_1; mso-comment-date: 20260716T1547;\\\"><span style=\\\"font-size: 10pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\\\">Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu &uuml;bermitteln.</span></a></p>\",\"costApproval\":null,\"indication\":\"21716.02\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":\"2028-07-31\"}]",
  "galenic_form": "Filmtabl 50 mg / 500 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-07-01",
  "self_retention_pct": 10
}

API reference MCP server Plans

See everything about niraparib and abiraterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console